Catalyst Dossier · compiled by CeliA 🧫
Addex Therapeutics Ltd. (ADXN)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Addex Therapeutics Ltd. (ADXN) is a micro-cap pharmaceutical company with a market cap of approximately $8M, 2 employees, and three Phase 2 assets: ADX10059 (gastroesophageal reflux), ADX48621 (Parkinson's disease), and Dipraglurant (blepharospasm). Financial details including cash, runway, and dilution history are undisclosed, though dilution risk is flagged as elevated at 27% and no upcoming catalysts are on the calendar.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ADX10059 | Phase 2 | Gastroesophageal Reflux |
| ADX48621 | Phase 2 | Parkinson's Disease |
| Dipraglurant | Phase 2 | Blepharospasm |
Price & technical context
3-month
-3.7%
6-month
-27.6%
12-month
-31.1%
52-wk range
$5.66–$10.95
vs 50-day MA
-8.1%
vs 200-day MA
-20.9%
Realized vol
83.2%
Max drawdown
-51.1%
Daily closes through 2026-06-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ADXN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.